Navigate BioPharma Services, Inc.
Carlsbad, CA
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (1)
○ EMA GMP
○ MHRA GMP
Quick Facts: Navigate BioPharma Services, Inc.
- Signal Score
- 60.0/100
- Quality Compliance
- Assessment pending
- Headquarters
- Carlsbad, CA
- Modalities
- Biomarker Services, Bioanalytical Services, Immunogenicity Testing, Flow Cytometry, Digital Pathology, CAR-T / Cell Therapy Analytics, Genomics / ddPCR, Spatial Biology, Pharmacokinetics / Pharmacodynamics
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
- Scored By
- CDMO Signal — independent CDMO intelligence platform
About Navigate BioPharma Services, Inc.
Auto-created by AI matchmaker. Data verification pending.
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesBiomarker Services, Bioanalytical Services, Immunogenicity Testing, Flow Cytometry, Digital Pathology, CAR-T / Cell Therapy Analytics, Genomics / ddPCR, Spatial Biology, Pharmacokinetics / Pharmacodynamics
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
60.0
Broad modality coverage (9 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press1 articles
Broad modality coverage (9 modalities)
Recent News 1 articles
Best practices for the development, analytical validation and clinical implementation of flow cytometric methods for chimeric antigen receptor T cell analyses - Wiley Online Library
Frequently Asked Questions About Navigate BioPharma Services, Inc.
What is Navigate BioPharma Services, Inc.'s CDMO Signal Score?
Navigate BioPharma Services, Inc. has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Navigate BioPharma Services, Inc. for a manufacturing program?
Use the free AI matchmaker to compare Navigate BioPharma Services, Inc. against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in: